Ọnwụnwa ụlọọgwụ ọhụrụ maka Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc., ụlọ ọrụ na-ahụ maka ọgwụ na-ahụ maka ụlọ ọgwụ lekwasịrị anya n'ịzụlite usoro ọgwụgwọ ọhụrụ maka ọgwụgwọ ọrịa kansa prostate, taa kwupụtara onye ọrịa mbụ dosed na ụlọ ọrụ na-akwado Phase 1/2 ọmụmụ iji nyochaa nchekwa, nnabata na mbido mbụ nke ESSA. Onye na-enyocha ngwaahịa na-edu ndú, EPI-7386, onye mbụ na-na-na klas N-terminal ngalaba androgen receptor inhibitor, yana Astellas Pharma Inc.'s na Pfizer Inc. metastatic castration na-eguzogide ọrịa prostate.

Print Friendly, PDF & Email

"Mmalite nke nnwale ngwakọta a na Astellas bụ oge mmiri maka ESSA ka anyị na-enyocha uru ụlọ ọgwụ nwere ike igbochi onye na-anabata androgen site na ụzọ abụọ nwere onwe ha na ọgwụgwọ nke ndị ọrịa nwere mCRPC bụ ndị na-enwetabeghị ọgwụgwọ na ọgbọ nke abụọ antiandrogen. ọgwụ,” ka Dr. David kwuru. R. Parkinson, Chief Executive Officer, ESSA Pharma Inc. "Ịjikọta usoro ọgwụgwọ abụọ anyị ga-etinye n'otu oge na nsọtụ abụọ nke androgen receptor. N'ụdị preclinical, anyị ahụla na ijikọta EPI-7386 na antiandrogens dị ugbu a nwere ike ibute mgbochi miri emi na nke sara mbara nke usoro ndu androgen. Ọnwụnwa nke oge 1/2 a bụ akara izizi nke usoro ọmụmụ ụlọ ọgwụ iji nyochaa EPI-7386 yana njikọta na ọgwụgwọ antiandrogen ugbu a na ndị ọrịa nwere mCRPC, yana nnwale mgbakwunye Phase 1/2 ndị a na-atụ anya ịmalite na 2022.

Usoro 1/2 nke ụlọ ọgwụ (NCT05075577) na-amalite site na akụkụ mbụ nke 1 ebe a na-edozi dose nke ọgwụ ọ bụla na-esote akụkụ nke abụọ ebe otu onye na-ahụ maka enzalutamide na-atụnyere nchikota nke enzalutamide na EPI-2. A na-atụ anya na ọmụmụ ihe nke 7386 ga-edebanye aha ruo ndị ọrịa 1 mCRPC bụ ndị a na-agwọbeghị ọgwụgwọ antiandrogen nke ọgbọ nke abụọ. Ebumnuche nke akụkụ nke 30 nke ọmụmụ ihe ahụ bụ inyocha nchekwa na nnabata nke ngwakọta ọgwụ wee guzobe usoro 1 akwadoro maka EPI-2 na enzalutamide mgbe ejiri ya na ngwakọta. A na-atụ anya na ọmụmụ ihe nke abụọ ga-edebanye aha ndị ọrịa 7386 mCRPC bụ ndị a na-agwọbeghị ọgwụgwọ antiandrogen nke ọgbọ nke abụọ. Ebumnuche nke akụkụ nke abụọ nke ọmụmụ ihe bụ iji nyochaa nchekwa, nnabata na ọrụ antitumor nke EPI-2 yana nchikota nke enzalutamide a kapịrị ọnụ ma e jiri ya tụnyere enzalutamide dị ka otu onye ọrụ.

Print Friendly, PDF & Email
Enweghị akara ọ bụla maka post a.

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment